Here is a scenario that is already happening in forward-thinking pharmacies across the country, and will be standard practice within five years. A patient with resistant hypertension wakes up each morning, steps on a Bluetooth-connected scale, and straps on a blood pressure cuff that automatically transmits to a cloud platform. Their pharmacist reviews the data stream between patient appointments, spots a three-day trend of creeping systolic pressure, calls the patient that afternoon, adjusts the ACE inhibitor dose under a collaborative practice agreement, and documents the intervention with a CPT code that generates $150 to $300 in monthly revenue.
That is not a vision. That is Remote Patient Monitoring, and it is running live with Medicare reimbursement right now.
The Market That Has Already Arrived
U.S. RPM revenue reached $12.76 billion in 2024 and is projected to reach $32.17 billion by 2032 at a compound annual growth rate of 12.3%. The U.S. RPM market alone exceeded $18 billion in 2026. And 46.3% of U.S. hospitals now offer RPM services.
This market is not emerging. It has emerged. The question is not whether RPM becomes part of pharmacy practice. It is whether your pharmacy is in it.
The Outcome Data That Should End the Debate
The Geisinger ConnectedCare365 Hypertension Management program is the clearest pharmacist-specific evidence in this space.
Up to 74% of adults with treatment-resistant high blood pressure, including those with chronic kidney disease, achieved blood pressure control below 140/90 mmHg within one year through a program combining remote blood pressure monitoring with pharmacist interactions. The program, presented at the American Heart Association’s Hypertension Scientific Sessions 2024, provided patients in central and northeast Pennsylvania communities with remote blood pressure monitoring devices that transmitted information to physicians and pharmacists who co-managed care and adjusted medications together.
Systolic blood pressure fell by an average of 3.3 mmHg per month for patients with initial readings above 150/90. “This team-based model signals a way to reduce hospitalization and improve blood pressure,” said senior study author Alexander Chang, MD, MS, a nephrologist at Geisinger Health.
BP telemonitoring with pharmacist case management is superior to usual care in controlling blood pressure among individuals with hypertension, with the evidence consistently showing this across rural, low-income, and underserved populations specifically. A retrospective analysis of 1,256 patients enrolled in a fully remote pharmacist-led hypertension RPM program found that 94.6% of patients reached their blood pressure goal during the period when the fully remote program was in place, compared with 75.8% pre-program.
In diabetes RPM trials, pharmacist-supported remote monitoring groups showed A1C reductions of 2.0% to 2.2% compared to 1.2% to 1.3% for non-RPM groups. The difference between those numbers is not a new drug. It is a pharmacist watching the data and acting on it between visits.
RPM programs reduce hospital readmissions by 25% to 50% for heart failure patients. The financial consequence of that reduction is not abstract: heart failure patients generate average annual savings of $8,000 per patient per year under RPM, and diabetes patients save $3,400 annually. A program that prevents just one heart failure readmission per month, at an average cost of $30,000 per readmission, generates $7,500 per month in additional value under a value-based arrangement structured around 25% of demonstrated savings. On top of standard billing.
The Medicare Billing Infrastructure That Already Exists
This is where most pharmacists stop reading because they assume RPM is a hospital-only billing mechanism. It is not.
Medicare CPT codes for RPM are live and paying right now.
CPT 99453 covers device setup and patient education at the initiation of RPM. CPT 99454 covers the device supply with daily recording or programmed alert transmissions. CPT 99457 covers the first 20 minutes of clinical staff time per month spent on monitoring and management. CPT 99458 covers each additional 20-minute increment. Remote Therapeutic Monitoring codes 98975 through 98981 now cover medication adherence, respiratory system status, and musculoskeletal system monitoring, expanding the billable surface area specifically to include the medication-related functions pharmacists are most qualified to perform.
CMS has established the monthly payment for RPM services in three tiers. CPT 99454 pays $48 to $55 per month for device supply. CPT 99457 pays $50 to $54 for the first 20 minutes of monthly management. CPT 99458 pays $40 to $43 for each additional 20-minute increment. For a patient requiring 40 minutes of monthly management, the monthly billing total for one enrolled patient reaches approximately $140 to $150. Across 100 enrolled patients, that scales to $14,000 to $15,000 monthly from billing alone, before any value-based savings arrangements.
A practice with 100 eligible patients enrolled in RPM may earn $20,000 to $30,000 per month in new revenue, depending on staff and software efficiencies.
In 2026, Federally Qualified Health Centers and Rural Health Clinics gained eligibility for these RPM codes, explicitly expanding access to the underserved populations that community pharmacists disproportionately serve. The patient populations with the highest burden of uncontrolled hypertension and diabetes are, by a wide margin, the same patients who rely most heavily on community pharmacy access.
Why the Pharmacist Is the Most Logical RPM Provider in Healthcare
Every argument for pharmacist-led RPM comes back to one structural fact: patients interact with their pharmacist more frequently than with any other healthcare provider.
The pharmacist sees the patient at every refill, every counseling visit, every point-of-care testing encounter, and every time the patient has a medication question between appointments. That access frequency is exactly what makes pharmacist-led RPM clinically powerful. The pharmacist who monitors a patient’s wearable data stream is the same person the patient already trusts to call when something feels off. No other clinician in the care team has that combination of data visibility and established relationship simultaneously.
The role description writes itself. Pharmacists interpret data collected from connected devices, collaborate with providers on treatment adjustments, document the intervention for billing, and help patients understand their results in real time. The pharmacist who builds this role is not adding a side service. They are becoming the continuous care layer that every chronic disease patient needs and almost none of them currently have.
The ADA 2026 Standards of Care, covered earlier in this newsletter, explicitly named expanded pharmacist roles in cardiorenal coordination. The 2026 AHA/ACC CKM Syndrome guideline, also covered in this newsletter, called for coordinated management across cardiovascular, kidney, and metabolic disease simultaneously. RPM is the operational tool that makes continuous cardiometabolic monitoring achievable at the community pharmacy level without a specialist appointment for every data point.
The Implementation Pathway for a Practice of Any Size
The key operational requirement for pharmacy-based RPM is a written order from a supervising physician establishing medical necessity, a collaborative practice agreement defining the pharmacist’s scope within the program, and an RPM platform that handles device distribution, data collection, and CPT code documentation.
Three RPM platforms have pharmacy-specific configurations currently available.
ThoroughCare offers population health and care management tools with RPM integration, built specifically for community pharmacy workflow. HealthArc provides an FDA-cleared RPM platform with pharmacy dashboard capabilities, billing support, and device management. Accuhealth is a turnkey RPM solution that provides cellular-connected devices, 24/7 monitoring, and a billing infrastructure that generates compliant CPT documentation.
All three offer implementation support and, in most cases, revenue-share models where upfront investment is limited and the platform’s fee is structured against the billing revenue generated.
The device categories relevant to pharmacy-led RPM are well-established. Cellular or Bluetooth-enabled blood pressure monitors for hypertension programs. Continuous glucose monitors or connected glucometers for diabetes. Connected weight scales for heart failure monitoring. Smart spirometers for COPD. Pulse oximeters for respiratory monitoring. Each device category connects to a specific clinical program and a specific CPT billing pathway.
Your 20-Patient Pilot This Week
The fastest path to a functioning RPM program is not a complete practice overhaul. It is a defined pilot with a specific patient cohort, a specific device, and a specific CPT billing target.
Identify your top 20 patients with resistant hypertension, uncontrolled diabetes, or heart failure. These are the patients who generate the highest clinical risk from inadequate between-visit monitoring, and the ones for whom the documented outcome data is strongest.
A 20-patient hypertension pilot using cellular blood pressure monitors can be structured in four steps. Select the platform and order the devices. Work with one supervising physician to establish the collaborative practice agreement and standing orders for medication adjustments. Enroll the 20 patients with device education and a 30-day check-in protocol. Document all monitoring time and interventions in the platform for CPT billing.
A 20-patient pilot generates approximately $2,800 to $3,000 monthly in direct billing revenue. More importantly, it generates a documented outcomes story and a workflow confidence base for scaling to 50, then 100 patients. A practice with 100 engaged RPM patients generates $20,000 to $30,000 monthly. The 20-patient pilot is the proof of concept that justifies the investment in scaling.
The pharmacist who builds this reads patients’ continuous data streams and acts on them in between appointments. That is not extra work. It is the work the future of pharmacy was always going to require. And Medicare is already paying for it.
Sources: American Heart Association / Hypertension Scientific Sessions 2024 (Chang et al., ConnectedCare365 Geisinger Study), AHA Newsroom (Remote Monitoring and Pharmacist Helped Improve Hard-to-Control Blood Pressure, September 2024), PMC (Remote Patient Monitoring Is Associated With Improved Outcomes in Hypertension: A Large Retrospective Cohort Analysis), PMC (Outcomes of Team-Based Digital Monitoring of Patients With Multiple Chronic Conditions), PMC (Home Blood Pressure Telemonitoring With Remote Hypertension Management in a Rural and Low-Income Population), ThoroughCare (Research Supports Remote Patient Monitoring for Hypertension Control), Precedence Research (Remote Patient Monitoring Market Size and Forecast to 2032), Exploding Topics (Remote Patient Monitoring Market Projections), CMS (RPM CPT Code Reimbursement Rates: 99453, 99454, 99457, 99458), CMS (RTM Codes 98975-98981 Final Rule), CMS (RPM Eligibility Expansion to FQHCs and RHCs, 2026)